Long Ideas - In the latter half of 2012, shares of Illumina (NASDAQ:ILMN) saw increased volatility, owing to the twin combination of takeover speculation regarding Roche (OTC:RHHBY), as … Continue Reading
Read nowLong Ideas - Earlier this week I had the pleasure of speaking with Alan Shortall, President and CEO of Unilife (NASDAQ:UNIS), about the company’s short and long-term prospects. … Continue Reading
Read nowLong Ideas - XenoPort (NASDAQ:XNPT) will deliver Phase III trial results for its lead pipeline candidate, Arbaclofen Placarbil, in early 2Q, and the company is moving forward on … Continue Reading
Read nowLong Ideas - In medicine, there are certain watershed moments that become an enduring part of medical history, such as the discovery of penicillin, or the eradication of … Continue Reading
Read nowLong Ideas - As the world’s largest biotechnology company, with a market capitalization well on its way to $70 billion, Amgen (NASDAQ:AMGN) represents the “old guard” of biotechnology. … Continue Reading
Read nowLong Ideas - With a gain of more than 27% over the past year, Celgene (NASDAQ:CELG) serves as a solid example of the balance between stability and growth … Continue Reading
Read nowQuick Picks - Biotech investors will be well-aware of the Dendreon (NASDAQ:DNDN) story – its rise to glory from 2009 to 2011 and subsequent fall from grace over … Continue Reading
Read now